Sorry, you need to enable JavaScript to visit this website.
Face of a woman with rosacea in her mid-50s grinning with right hand on cheek

Get patients started toward rosacea relief

Galderma CAREConnect Card

Your patients may pay as little as $20 to $75

The Galderma CAREConnect Patient Savings Card* allows the prescriptions you write to be easily filled by any participating pharmacy while giving your commercially insured patients the ability to pay less out-of-pocket.

GET SAVINGS CARD
Cropped view of the EPSOLAY cream bottle on the right with EPSOLAY cream smeared on the left
EPSOLAY cream application instructions

Patients can use it daily as prescribed, either in the morning or evening.1

DOWNLOAD INSTRUCTIONS FOR USE

USING EPSOLAY CREAM IS AS EASY AS C-A-M-P:

WATCH HOW TO USE VIDEO
Woman with rosacea in her mid-30s cupping water in both hands and raising to face
1
Cleanse

Use a mild cleanser like Cetaphil® Gentle Skin Cleanser, gently rinse your face, and pat completely dry with a soft towel.1

Woman with rosacea in her mid-30s putting pea-sized amount of EPSOLAY cream on left cheek
2
Apply

Lightly massage a pea-sized amount of EPSOLAY cream onto each area of your face (forehead, chin, nose, and cheeks). Avoid your eyes, lips, and mouth and let dry.1

Wash your hands, as the cream may stain or bleach fabric.1

Woman with rosacea in her mid-30s touching hand to left cheek
3
Moisturize

After the medication has dried, use a moisturizer like Cetaphil® Moisturizing Lotion.1

Face of a woman with rosacea in her mid-30s looking forward
4
Protect

If you decide to use EPSOLAY cream as part of your morning routine, be sure to use a daily sunscreen to protect your skin!1

  • Tips for using
    EPSOLAY cream1

  • Illustration of EPSOLAY cream bottle

    Before you use EPSOLAY cream for the first time, prime the pump by pressing down until the first drop of cream is dispensed.

  • Illustration of sun with rays

    Make sure to limit your time in sunlight or artificial light. EPSOLAY cream may make your skin more sensitive to the sun and the light.

  • Illustration of EPSOLAY cream bottle with cap on

    Your bottle of EPSOLAY cream should be stored at room temperature (68 ℉ to 77℉).

  • Illustration of trash can with lid

    Please discard your bottle of EPSOLAY cream 30 days after your first use or by printed expiration date, whichever comes first.

  • Illustration of EPSOLAY cream bottle with cap on encompassed by cyclical arrows

    Be sure to refill EPSOLAY cream right away, so you can continue to use it after your bottle is finished.

Open brochure

Download a printable brochure

FOR YOU FOR YOUR PATIENTS

*Certain limitations may apply. Click here for program details.

††The Galderma® CAREConnectTM Program (“Program”) is brought to you by Galderma Laboratories, L.P. (“Galderma”). The Program is only available for commercially unrestricted or commercially restricted/cash paying patients at participating pharmacies. Patients who are enrolled in state or federally government-run or government-sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CAREConnect Patient Savings Card (“Card”). Any claim under the Program must be submitted by participating pharmacies to one of the Administrators of the Program.

Reference: 1. EPSOLAY (benzoyl peroxide) cream, 5% [Prescribing Information]. Whippany, NJ: Sol-Gel Technologies Ltd.; April 2021.

IMPORTANT SAFETY INFORMATION

Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. Warnings/Precautions: Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin Irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

IMPORTANT SAFETY INFORMATION

Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. Warnings/Precautions: Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin Irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Thank you for your interest in staying up to date on EPSOLAY cream.

Sign up for updates about EPSOLAY cream and additional information about rosacea.

HOME

Stay in the know

Register for updates about EPSOLAY cream and additional related clinical information.

Please enter first name
Please enter last name
Please enter ZIP code
Please select job role
Please enter NPI
Please select job role
Please agree to the Terms of Use and Privacy Policy
By completing and submitting this form, you grant permission and agree to allow Galderma Laboratories, L.P., and its affiliates (“Galderma”) to collect the information you provide so that Galderma may market or advertise to you across multiple channels regarding EPSOLAY cream. Galderma will not sell or share this information with third parties. For additional information regarding how Galderma handles your information, please see our privacy policy.
*Required. *Please enter the fields above.

Request a visit or information from a sales representative

The Sales Representative Request Form is a resource for healthcare professionals. Please complete the form below, and you will be contacted by a Galderma sales representative.

Please enter first name
Please enter last name
Please enter office address
Please enter city
Please enter state
Please enter ZIP code
Please enter email
Please enter phone
Please select preferred contact
Please select job role
Please select job role
Please select specific request
Please enter NPI number
Please agree to the Terms of Use and Privacy Policy
Please agree to the Terms of Use and Privacy Policy
By completing and submitting this form, you grant permission and agree to allow Galderma Laboratories, L.P., and its affiliates (“Galderma”) to collect the information you provide so that Galderma may market or advertise to you across multiple channels regarding EPSOLAY cream. Galderma will not sell or share this information with third parties. For additional information regarding how Galderma handles your information, please see our privacy policy.
*Required. *Please enter the fields above.
   
   

Thank you for your interest in staying up to date about EPSOLAY cream.

Your submission has been confirmed.

Want to discuss EPSOLAY cream with a Galderma representative?

    SUBMIT REQUESTHOME
   
   
   

Thank you for your interest in additional information about EPSOLAY cream.

Your request for more information has been confirmed.

    HOME    

STUDY DESIGN3

The safety and efficacy of EPSOLAY cream was evaluated in 2 multicenter, randomized, double-blind, vehicle-controlled trials in patients with moderate to severe papulopustular rosacea. In Pivotal Trial 1, 243 patients used EPSOLAY cream and 118 used vehicle cream. In Pivotal Trial 2, 250 patients used EPSOLAY cream and 122 used vehicle cream.

Patients were treated once daily for 12 weeks with either EPSOLAY cream or vehicle cream.

Patients were required to have a minimum of 15 to 70 total inflammatory lesions (papules and/or pustules) and no more than 2 nodules (where a nodule was defined as a papule or pustule greater than 5 mm in diameter) and an Investigator Global Assessment (IGA) score of 3 (moderate) or 4 (severe) at baseline.

At baseline, patients had a mean inflammatory lesion count of 27.5, 89% were scored as moderate (IGA=3), and 11% scored as severe (IGA=4).

The coprimary efficacy endpoints in both trials were the proportion of patients with treatment success at Week 12, defined as an IGA score of 0 (clear) or 1 (almost clear) with at least a 2-grade reduction from baseline, and the absolute change from baseline in inflammatory lesion counts at Week 12.

STUDY DESIGN4

The long-term safety and tolerability of daily use of EPSOLAY cream were evaluated in an open-label, long-term safety study in papulopustular rosacea patients from the 2 double-blind pivotal trials. A total of 547 patients were enrolled, including 363 patients previously treated with EPSOLAY cream and 184 patients previously treated with vehicle cream.

Patients were treated with EPSOLAY cream once daily from baseline through Week 40 with an IGA score for rosacea assessed as mild, moderate, or severe. If a patient was assessed as clear or almost clear, patients were not dispensed the study product until relapse was assessed.

Patients were required to have completed 12 weeks or be within the Week 12 window time (±4 days) of the double-blind treatment period of the pivotal trials and missed not more than 1 visit of Visits 3, 4, or 5 in the pivotal trials.

At baseline, patients had a mean inflammatory lesion count of 28.4, 89.2% were scored as moderate (IGA=3), and 10.8% were scored as severe (IGA=4).

Safety was evaluated by monitoring adverse events, cutaneous safety (dryness and scaling), and local tolerability (itching and burning/stinging) assessments, physical examinations, and vital signs. The study was not intended to assess efficacy. Certain efficacy data and endpoints were, however, summarized.

Are you a healthcare professional?

The information contained in this section of the website is intended for US healthcare professionals only.